GlassScriptPhysician profile
Trishala Meghal
NPI 1255691135
$7,638.54
in general payments reported to CMS, 2019-2025
34 companies · $1,437 in 2025
The $1,437 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $1,050 · 2021: $63.22 · 2022: $46.69 · 2023: $2,595 · 2024: $2,135 · 2025: $1,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,085 · Food and Beverage: $1,418 · Honoraria: $360 · Education: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,085.00 |
| Food and Beverage | $1,418.13 |
| Honoraria | $360.00 |
| Education | $303.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,264.44 | 2019-2025 | Enhertu, Lynparza, Imfinzi |
| Immunomedics, INC. | $1,050.00 | 2020 | |
| Daiichi Sankyo INC. | $665.22 | 2022-2025 | Enhertu, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $221.23 | 2019-2025 | Opdivo, Opdualag |
| Regeneron Healthcare Solutions, INC. | $147.80 | 2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $143.64 | 2022-2025 | Zejula, Jemperli, Ojjaara |
| Gilead Sciences, INC. | $130.92 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $84.74 | 2019 | |
| Seagen INC. | $78.99 | 2025 | |
| Novartis Pharmaceuticals Corporation | $63.87 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $61.96 | 2019-2025 | Keytruda, Keytruda Qlex |
| Array Biopharma INC | $59.36 | 2025 | Braftovi, Mektovi, Lorbrena |
| Bayer Healthcare Pharmaceuticals INC. | $53.92 | 2025 | |
| Abbvie INC. | $52.58 | 2025 | |
| Incyte Corporation | $48.57 | 2019-2025 | Jakafi |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $44.46 | 2019 | |
| Celgene Corporation | $42.75 | 2021-2024 | Reblozyl |
| Taiho Oncology, INC. | $40.90 | 2025 | |
| Pharmaessentia USA Corporation | $37.26 | 2025 | Besremi |
| Janssen Biotech, INC. | $36.90 | 2025 | Talvey, Darzalex, Tecvayli |
| Eisai INC. | $36.12 | 2025 | |
| Genzyme Corporation | $32.86 | 2019-2025 | |
| Pfizer INC. | $32.05 | 2019-2025 | |
| Tesaro, INC. | $28.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $24.56 | 2024 | Myrisk |
| Pharmacosmos Therapeutics INC. | $19.40 | 2025 | Monoferric |
| Tersera Therapeutics LLC | $18.53 | 2019 | |
| Astellas Pharma US INC | $18.53 | 2025 | Xtandi |
| Beone Medicines USA, INC. | $18.30 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $16.94 | 2025 | |
| Geron Corporation | $16.66 | 2025 | Rytelo |
| Stemline Therapeutics INC. | $16.53 | 2025 | Orserdu |
| Dendreon Pharmaceuticals LLC | $15.64 | 2024 | Provenge |
| Alexion Pharmaceuticals, INC. | $14.91 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trishala Meghal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.